Beranda › Kanker Paru Non-Sel Kecil › Oklahoma › Oklahoma City
Uji klinis Kanker Paru Non-Sel Kecil di Oklahoma City, OK
28 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Oklahoma City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Menerima pesertaFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- University of Oklahoma, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Menerima pesertaFase 3
- Local Institution - 0418, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Menerima pesertaFase 3
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Menerima pesertaFase 2/3
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- University of Oklahoma, Oklahoma City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Site, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Menerima pesertaFase 1/2
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Menerima pesertaFase 1
- OU Health Stephenson Cancer Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Menerima pesertaFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Menerima pesertaFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Menerima pesertaStudi observasional
- Mercy Hospital - OKC, Oklahoma City
Study of XB010 in Subjects With Solid Tumors
Menerima pesertaFase 1
- Stephenson Cancer Center, Oklahoma City
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Menerima pesertaFase 1
- OU Stephenson Cancer Center, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Mercy Hospital Oklahoma City, Oklahoma City
GEMINI-NSCLC: NSCLC Biomarker Study
Menerima pesertaStudi observasional
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Menerima pesertaFase 1
- Dren Investigational Site, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
Menerima pesertaFase 1
- University of Oklahoma, Oklahoma City
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Oklahoma City
- Kanker Ovarium28 studi
- Kanker Endometrium25 studi
- Kanker Kolorektal22 studi
- Kanker Prostat21 studi
- Kanker Paru19 studi
- Kanker Payudara17 studi
- Kanker Metastatik16 studi
- Kanker (semua jenis)14 studi
- Leukemia Mieloid Akut14 studi
- Karsinoma Sel Skuamosa Kepala dan Leher13 studi
- Kanker Kandung Kemih11 studi
- Kanker Pankreas11 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.